Page 5,179«..1020..5,1785,1795,1805,181..5,1905,200..»

Stem Cell Therapy- Victoria Hicks – Video

Posted: Published on June 8th, 2013

Stem Cell Therapy- Victoria Hicks By: Victoria Hicks … Continue reading

Comments Off on Stem Cell Therapy- Victoria Hicks – Video

The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 1) – Video

Posted: Published on June 8th, 2013

The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 1) Professor Arnold Caplan of Case Western Reserve University is widely regarded as "The Father of the Mesenchymal Stem Cell". This lecture is a "must see" for ... By: http://www.cellmedicine.comContinue reading

Comments Off on The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 1) – Video

Stem Cell Enhancing Therapy 9 – Video

Posted: Published on June 8th, 2013

Stem Cell Enhancing Therapy 9 http://robinbnavarro.com/ http://virtual-reality.asia/ http://globalvirtualexpress.com/ http://boracayvirtualtour.com/ http://cebuvirtualtour.com/ By: Robin Navarro … Continue reading

Comments Off on Stem Cell Enhancing Therapy 9 – Video

Amid budget cuts to higher education, KU gets funding for adult stem cell center

Posted: Published on June 8th, 2013

Topeka As Kansas University officials bemoaned legislative budget cuts this week, Kansas Board of Regents member Ed McKechnie wondered if those cuts could be alleviated somewhat by diverting funds that KU received in another area but didn't request. McKechnie, of Arcadia, was talking about the $2 million allocated over two years to create and run the Midwest Stem Cell Therapy Center at the KU Medical Center. "Stem cell research is good, but I don't know if that's what we need to do right now," McKechnie said. "Might be a good idea to use that to offset other things." Republicans pushed through an appropriations bill that cuts higher education by $66 million over 2 years. Regents blasted the cuts but conceded there was little they could do about them except ask Gov. Sam Brownback to make higher education funding a priority next year. But amid the cuts, legislators also approved the creation of the stem cell research center at KU, a center that KU officials did not ask for during the appropriations process. The center will work on adult stem cell, cord blood and related stem cell research, providing therapies to patients and serving as a clearinghouse for physicians on cutting-edge … Continue reading

Comments Off on Amid budget cuts to higher education, KU gets funding for adult stem cell center

Regent questions spending on KU stem cell center

Posted: Published on June 8th, 2013

LAWRENCE, Kan. (AP) Instead of committing $2 million to a project the University of Kansas didn't request, state lawmakers should have used the money on something else more important to the school, a member of the state's Board of Regents said. In its recently completed session, the Legislature approved an appropriations bill that cuts higher education funding by $66 million over two years, The Lawrence Journal-World (http://bit.ly/14G7Zl8) reported. Legislators also approved spending $2 million over the same span to create the Midwest Stem Cell Therapy Center at Kansas University Medical Center. "Stem cell research is good, but I don't know if that's what we need to do right now," said Ed McKechnie, a regent from Arcadia. "Might be a good idea to use that to offset other things." The Board of Regents has criticized the spending cuts but conceded there was little they could do beyond ask Gov. Sam Brownback to make funding for higher education a priority next year. While united in their disappointment with the cuts, the board members aren't unanimous in how they feel about the stem cell center. Regents Vice Chairman Fred Logan said he disagrees that the $2 million should be spent elsewhere. "I'm all … Continue reading

Comments Off on Regent questions spending on KU stem cell center

Roy Jones

Posted: Published on June 8th, 2013

Roy Jones Charles Martinez: Comprehensive Stem Cell Transplant Outcome Electronic Data Submission Roy Jones Charles Martinez, MD Anderson Cancer Center present Comprehensive Stem Cell Transplant Outcome Electronic Data Submission. By: NCIgov … Continue reading

Posted in Stem Cell Transplant | Comments Off on Roy Jones

Opulence Aesthetic Medicine on Married to Medicine – Video

Posted: Published on June 8th, 2013

Opulence Aesthetic Medicine on Married to Medicine Lisa performs tattoo removal using the aerolase on Quad. By: opulencecs … Continue reading

Posted in Aesthetic Medicine | Comments Off on Opulence Aesthetic Medicine on Married to Medicine – Video

Cell therapy may regenerate liver cells

Posted: Published on June 8th, 2013

Washington, June 7 (IANS) Researchers have shown that cell therapy may be used in liver disease to regenerate liver cells, says a study. Investigators discovered that a human embryonic stem cell can be differentiated into a previously unknown liver progenitor cell, an early offspring of a stem cell, and produce mature and functional liver cells, reports Science Daily. "The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said the study's senior author, Valerie Gouon-Evans, PharmD, Ph.D., assistant professor in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sinai. "Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem." The study has been published in the journal Cell Stem Cell Friday. Read the original here: Cell therapy may regenerate liver cells … Continue reading

Comments Off on Cell therapy may regenerate liver cells

Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program

Posted: Published on June 8th, 2013

SAN DIEGO, CA--(Marketwired - Jun 7, 2013) - Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia.As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury. "We are pleased with the responses that we have provided to the FDA and look forward to initiating our clinical trials," stated David Koos, Chairman and CEO of Regen BioPharma. "Although it is possible that a second round of comments may be issued, we feel this process is extremely useful to creating a clinical trial that is optimized for safety and detection of efficacy." The HemaXellerate clinical trial aims to recruit 10 patients with aplastic anemia that have not shown material signs of improvement under the current the standard of care.If successful, the company will progress to larger efficacy-finding trials, as well as expansion to other diseases that would benefit from enhancement of bone marrow stem cells. The scientific rationale for HemaXellerate, … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program

BioTime, Inc. Closes on $9 Million Financing

Posted: Published on June 8th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966. BioTime intends to use the net proceeds from the sale of its common shares and warrants for working capital and other general corporate purposes, and may invest a portion of the proceeds in one or more of its subsidiaries, including funding of the expansion of the LifeMap Sciences, Inc. product development and research programs. The common shares and warrants, and the shares issuable upon exercise of the warrants, were sold pursuant to a prospectus supplement dated as of June 3, 2013, which has been filed with the Securities and Exchange Commission (SEC) in connection with a takedown from the Companys shelf registration statement on Form S-3 (File No. 333-183557), which became effective on September 7, 2012, and the base prospectus dated September 7, 2012. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SECs website at http://www.sec.gov. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is … Continue reading

Posted in Stem Cell Human Trials | Comments Off on BioTime, Inc. Closes on $9 Million Financing

Page 5,179«..1020..5,1785,1795,1805,181..5,1905,200..»